Astrana Health stock has climbed 18.5% over the past year yet remains down about 54.0% over five years, which leaves investors weighing a recent rebound against a longer period of weaker returns and a share price that screens as overvalued on earnings multiples. The question for anyone looking at Astrana Health now is whether the current price already reflects the business progress implied by recent revenue and earnings updates.

• The share price decline of about 54.0% over five years points to a company that has not rewarded long term holders despite more recent gains.
• Recent revenue and earnings momentum can support higher expectations for future cash generation. However, any setback in growth or margin performance may quickly pressure a valuation that already looks full on traditional multiples.
• Astrana Health scores 3 out of 6 on the valuation checks, which signals a mixed picture rather than a clear bargain or clear overvaluation across the broader tests.

The issue now is whether Astrana Health's current valuation leaves enough room for error if growth or profitability does not keep pace with what the market appears to be pricing in.

Has Astrana Health Run Too Far on Earnings?

The P/E ratio suits Astrana Health because it already reports positive earnings that investors can compare directly with the share price. Astrana Health currently trades on about 41.9x earnings, which is well above the Healthcare sector average of roughly 24.7x and the peer group average of about 26.7x. That means investors are paying a higher price for each dollar of current earnings than is typical across similar companies.

The fair P/E implied by the broader model is around 36.3x, which is still high but below where Astrana Health trades today. Despite the strong Q2 2026 earnings beat and the positive share price reaction, the stock price already stands ahead of what this tailored fair multiple suggests. The gap between the current P/E and both the fair ratio and sector norms points to a valuation that leaves less room for disappointment if earnings growth slows.

On the P/E multiple, Astrana Health appears overvalued compared with both its modelled fair ratio and Healthcare peers.

The Astrana Health Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where Astrana Health's valuation puzzle leaves off by spelling out which assumptions about Astrana Health's future growth, margins and earnings would need to hold for the stock to be worth meaningfully more or less than it is today, and they sit on Simply Wall St's Community page. Each narrative treats fair value as a thesis about Astrana Health's business that you can track over time, rather than a one off snapshot.

One of the top community narratives on Astrana Health: 31% undervalued

"Continued transition to full risk, value-based care contracts is driving recurring, higher-quality revenue streams and improved patient retention, positioning Astrana to benefit from rising demand…"

Do you think there's more to the story for Astrana Health? Head over to our Community to see what others are saying!

The Bottom Line

Astrana Health now looks overvalued on its P/E multiple compared with both sector averages and the tailored fair ratio, so the market is already giving the company credit for robust earnings delivery. With broader valuation checks landing in a mixed zone rather than clearly cheap, the key question is whether Astrana Health can keep growing earnings and protecting margins strongly enough to justify that premium. For any investor considering the stock, the crux is whether current expectations prove sustainable or whether even a modest wobble in execution leads to a reset in the multiple.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.